About This Fund
Ouroboros Family Founders Fund I, LP is a private equity fund targeting up to $1 billion in committed capital, managed by Ouroboros, a New York-based private activist investment sponsor. The fund was established to apply a differentiated 'Dequity' investment model — a proprietary structure that combines equity-like return potential with debt-like income characteristics — designed to align the interests of investors, management teams, and operating companies over the long term. Ouroboros employs a proprietary AI-driven identification platform, Serpentel®, to source and evaluate investment opportunities in sectors including healthcare, sustainable technologies, and consumer services.
The fund targets founder-led, family-linked, or employee-owned companies with investment sizes ranging from $10 million to $100 million per transaction. The strategy focuses on businesses where Ouroboros can act as a constructive active investor, working alongside owner-operators to accelerate growth, optimize capital structure, and align value creation with governance principles. The fund's investment mandate spans community wellness and better living — encompassing healthcare innovation, sustainability-oriented businesses, and consumer-facing enterprises with strong operating cultures.
Ouroboros Family Founders Fund I demonstrated its investment approach with its lead role in a $60 million Series A financing for Cytotheryx, a cell therapy platform company developing treatments for liver disease. The fund is headquartered in New York City and accepts both anchor and follow-on capital commitments from qualified institutional and high-net-worth investors seeking differentiated private equity exposure.